Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03487-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Manuel Valladares-Ayerbes und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen del Rocío, Instituto de Biomedicina, 41013, Seville, Spain. mvalaye@icloud.com. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Mutation, Cell-Free Nucleic Acids, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by AMGEN S.A..
Abstract (Originalsprache)
Purpose
RAS ( KRAS / NRAS ) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS mutational status by tumor-tissue biopsy is essential in guiding the optimal treatment decision for mCRC. RAS mutations are negative predictive factors for the use of EGFR monoclonal antibodies. Cell-free DNA (cfDNA) analysis enables minimally invasive monitoring of tumor evolution. Methods/patients PERSEIDA was an observational, prospective study assessing cfDNA RAS , BRAF and EGFR mutations (using Idylla™) in first-line mCRC, RAS wild-type (baseline tumor-tissue biopsy) patients (cohort 2). Plasma samples were collected before first-line treatment, after 20 ± 2 weeks, and at disease progression.
Results
117 patients were included (103 received panitumumab + chemotherapy as first-line treatment). At baseline, 7 (6.8%) patients had RAS mutations, 4 (3.9%) BRAF mutations and no EGFR mutations were detected (cfDNA, panitumumab + chemotherapy subpopulation [panitumumab + Ch]). The baseline RAS mutational status concordance between tissue and liquid biopsies was 94.0% (93.2%, panitumumab + Ch). At 20 weeks, only one patient in the study (included in the panitumumab + Ch) had an emerging cfDNA RAS mutation. No emerging BRAF or EGFR mutations were reported. At disease progression, 6 patients had emergent mutations not present at baseline ( RAS conversion rate: 13.3% [6/45]; 15.0% [6/40], panitumumab + Ch).
Conclusions
The concordance rate between liquid and solid biopsies at baseline was very high, as previously reported, while our results suggest a considerable emergence of RAS mutations during disease progression. Thus, the dynamics of the genomic landscape in ctDNA may provide relevant information for the management of mCRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Virgen del Rocío, Instituto de Biomedicina, 41013, Seville, Spain. mvalaye@icloud.com.
- Consorcio Hospital General Universitario de Valencia, Universidad de Valencia, Valencia; CIBERONC, Valencia, Spain.
- Hospital Universitario Virgen de las Nieves, Granada, Spain.
- Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain.
- Hospital Universitario Reina Sofía, Córdoba, Spain.
- Hospital Universitario de Burgos, Burgos, Spain.
Förderung
- This study was funded by AMGEN S.A.
Zitieren
APA
Valladares-Ayerbes, M., Safont, M. J., González Flores, E., García-Alfonso, P., Aranda, E., Muñoz, A. L., Falcó Ferrer, E., Cirera Nogueras, L., Rodríguez-Salas, N., Aparicio, J., Llanos Muñoz, M., Pimentel Cáceres, P. P., Castillo Trujillo, O. A., Vidal Tocino, R., Salgado Fernández, M., Salud-Salvia, A., Massuti Sureda, B., Garcia-Carbonero, R., Vicente Conesa, M. Á., …, & PERSEIDA investigators (2024). Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03487-4
Vancouver
Valladares-Ayerbes M, Safont MJ, González Flores E, García-Alfonso P, Aranda E, Muñoz AL, et al. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03487-4
BibTeX
@article{ValladaresAyerbes2024,
author = {Valladares-Ayerbes, Manuel and Safont, Maria José and González Flores, Encarnación and García-Alfonso, Pilar and Aranda, Enrique and Muñoz, Ana-Maria López and Falcó Ferrer, Esther and Cirera Nogueras, Luís and Rodríguez-Salas, Nuria and Aparicio, Jorge and Llanos Muñoz, Marta and Pimentel Cáceres, Paola Patricia and Castillo Trujillo, Oscar Alfredo and Vidal Tocino, Rosario and Salgado Fernández, Mercedes and Salud-Salvia, Antonieta and Massuti Sureda, Bartomeu and Garcia-Carbonero, Rocio and Vicente Conesa, Maria Ángeles and Lloansí Vila, Ariadna and PERSEIDA investigators, PERSEIDA investigators},
title = {Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03487-4}
}
EUVIMED